Mabion S.A., a Poland-based biotech, has signed a long-term development and commercialization agreement with Mylan Ireland. The agreement gives Mylan exclusive rights to sell Mabion’s biosimilar of Mabthera/Rituximab (Mabion CD20) in all EU countries and non EU Balkan states. Mylan will support Mabion in Mabion’s effort to secure approval of Mabion CD20 by the European Medicine Agency. Mylan will pay Mabion an upfront payment of $10 million and additional milestone payments in the aggregate o...